IBSA USA’s Post

𝐈𝐫𝐨𝐧𝐰𝐨𝐨𝐝 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐑𝐞𝐬𝐮𝐥𝐭𝐬 𝐟𝐨𝐫 𝐀𝐩𝐫𝐚𝐠𝐥𝐮𝐭𝐢𝐝𝐞 𝐢𝐧 𝐆𝐈 𝐚𝐆𝐕𝐇𝐃 Ironwood Pharmaceuticals (Nasdaq: IRWD) Ironwood Pharmaceuticals announces positive Phase II results for apraglutide in patients with steroid-refractory gastrointestinal acute Graft-versus-Host Disease (SR GI aGVHD). Apraglutide, a next-generation GLP-2 analog, showed promising safety and tolerability in combination with standard therapy. Majority of patients responded to treatment by Day 28 and maintained response through Day 91. Dr. Robert Zeiser, Principal Investigator, highlights apraglutide's potential in managing acute GI GVHD. GI aGVHD is a life-threatening complication post HSCT, affecting a significant number of patients. Ironwood's Chief Medical Officer, Dr. Michael Shetzline Michael Shetzline, emphasizes apraglutide's role in addressing high unmet medical needs. Stay tuned for additional data from the STARGAZE trial at upcoming medical congresses. #GIHealth #GraftVersusHostDisease #Apraglutide #ClinicalTrial #MedicalResearch #Hematology #Immunotherapy #HSCT

Hope you have fixed your meetings for following discussions 1) Injectables and ophthalmics fillings in regulated markets and possible collaboration 2) ROW market - basket of products from different therapeutics including crtitical care and anesthesia 3) Absolute low hanging markets entry based on EU approvals

The March 20 FDA approval of aprocitentan (Tryvio; Idorsia Pharmaceuticals Ltd) represents a historic moment for #hypertension specialists. In this interview we spoke with PRECISION investigator Michael Weber, MD, about the significance of the approval, how to communicate with patients about the REMS program, and what clinicians need to know about the dual endothelin receptor's mechanism of action in managing hypertension. Learn more: https://lnkd.in/eXupdkrW #Cardiology #FDANews

Deciphering the Genesis of "EVENITY®" Unveiling the Naming Journey of Amgen's Osteoporosis Breakthrough In the realm of pharmaceuticals, a name holds immense power—it's not just a label, but a gateway to understanding, trust, and hope. Such is the case with " EVENITY®" the name crafted by Brand Acumen for Amgen's revolutionary prescription medicine aimed at treating osteoporosis in postmenopausal women at high risk of fracture. Behind this seemingly simple name lies a rich tapestry of associations and connotations. At its core, "EVENITY®" embodies a sense of balance, harmony, and equilibrium—a fitting tribute to its intended purpose of restoring strength and stability to bones weakened by osteoporosis. The word "even" suggests a state of uniformity, consistency, and regularity—a stark contrast to the fragility and unpredictability often associated with osteoporosis. It evokes a sense of symmetry and order, reflecting the medicine's goal of restoring bone density and integrity. The '-ity' suffix has a duality of messaging; one of 'longevity' and 'density' (bone density). As a treatment designed to address the debilitating effects of osteoporosis, the name encapsulates its core mission of restoring balance and uniformity to bone health. By evoking notions of evenness and regularity, "EVENITY®" paints a vivid picture of hope and healing for those affected by osteoporosis. "EVENITY®" serves as more than just a name—it's a beacon of promise and progress in the fight against osteoporosis. By providing a sense of stability and reassurance, it empowers patients to take control of their health and embrace a future free from the constraints of bone fragility. #pharmaceuticalindustry #pharmamarketing #naming #branding #medicalaffairs #brandname #brandnarrative #brandacumen #naming #drugnaming #drugdevelopment

The innovative formulation of Rabeprazole and Domperidone in a sustained release capsule. This combination has shown promising results in the treatment of gastroesophageal reflux disease (GERD) and other related conditions. The sustained release formulation ensures a longer duration of action, improving patient compliance and outcomes. Let’s discuss the impact of such advancements in the field of pharmacology and how it can revolutionize patient care in gastroenterology.” #Rabifriz, #Darmaan pharma

📌 | Oncology Board Book 2024. 📍 | Board of Pharmacy Specialties. ⚠️ | Mention someone who’s interested, And for more updates, Follow The Hashtag #TheGoodPharmacist https://lnkd.in/dZXnGgaE ⚠️ | Always remember to be the good pharmacist you wish to see. #Pharmacist #Pharmacy #Clinicalpharmacy #Hospitalpharmacy

🔍 Significant advancements unfold at Apellis Pharmaceuticals as they identify a potential explanation for the rare cases of retinal vasculitis linked to Syfovre, their recently endorsed GA treatment. Through thorough examination, Apellis discovered "internal structural variations" in 19-gauge needles found in certain injection kits. While a direct correlation is yet to be established, they recommend a complete transition to 18-gauge needles for enhanced safety measures. 👉 Learn more about these findings in this article from Eyewire+ #AMD #Ophthalmology #HealthcareInnovation #EyeHealth #EyeSurgery #Biotech #Medtech #Lifescience

PET Mycardial Perfusion Imaging for the detection of Coronary Artery Disease will be far better than the current modalities we are using till now.. It will open a new era in #CardiacImaging .

Listen in from a PBM's perspective! Prerakkumar Parikh, PharmD, director of specialty clinical solutions at Magellan Rx Management, touches on the recent FDA approvals of the first MS biosimilar and the first tocilizumab biosimilar.

Stay Up-to-Date on #PharmacyTrends with Drug Topics! Check out these insightful interviews from Drug Topics this month: ⭐ Could a New Therapy Revolutionize Pain Management? Hear Albert Dahan discuss cebranopadol's potential to address current gaps in pain management strategies. ⭐ Independent Pharmacy Powerhouse: Grubb's Pharmacy's Michael Kim and Joan Kim, the husband-and-wife team behind a thriving independent pharmacy in Washington D.C. ⭐ The Future of Fair Pricing: Pharmaceutical Care Management Association (PCMA)'s Johnny Garcia delves into the complexities of drug pricing and the role of the pharmaceutical supply chain. PLUS! Advocacy Efforts for Pharmacies at the Federal Level (American Pharmacies) RxCash+ Tool to Streamline Pharmacy Operations (RedSail Technologies) Cold Chain Technology for Proper Medication Storage (Phononic Inc) Head over to Drug Topics for the full interviews! #Pharmacy #PainManagement #DrugPricing #IndependentPharmacy #Technology #ColdChain #Nephrolithiasis https://lnkd.in/esxjYdRW